Logo

Avecia and TriLink to Integrate Technology

Feb 27, 2006

This article has been updated from a previous version to include additional information about the partnership.

NEW YORK, Feb. 27 (GenomeWeb News) - Avecia and TriLink announced today they will adopt common technology to offer customers "seamless" scale-up in oligo development and manufacturing.

 

Avecia is a GMP oligo manufacturer based in Millford, Mass., while TriLink, based in San Diego, is a custom oligonucleotide manufacturer with a focus on the discovery and pre-clinical stages of drug discovery.

 

The companies said that the alliance will speed the manufacture of oligos for drug discovery, development, and commercialization, and will offer an option for drugmakers "looking to minimize the challenges and risks associated with transitioning from a research-grade vendor to an oligonucleotide development service and manufacturing company."

 

Benefits of the common technology platform include "regulatory simplicity, cost control, time savings and risk minimization," the companies said.

Breaking News
The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.